Wilson disease protein

Wilson disease protein (WND), also known as ATP7B protein, is a copper-transporting P-type ATPase which is encoded by the ATP7B gene. The ATP7B protein is located in the trans-Golgi network of the liver and brain and balances the copper level in the body by excreting excess copper into bile and plasma. Genetic disorder of the ATP7B gene may cause Wilson's disease, a disease in which copper accumulates in tissues, leading to neurological or psychiatric issues and liver diseases.

ATP7B
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesATP7B, PWD, WC1, WD, WND, ATPase copper transporting beta
External IDsOMIM: 606882 MGI: 103297 HomoloGene: 20063 GeneCards: ATP7B
Orthologs
SpeciesHumanMouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_000053
NM_001005918
NM_001243182
NM_001330578
NM_001330579

NM_007511

RefSeq (protein)

NP_031537
NP_001390638

Location (UCSC)Chr 13: 51.93 – 52.01 MbChr 8: 22.48 – 22.55 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse
Physiological pathway of copper in human body. Cu = copper, CP = ceruloplasmin, ATP7B protein is in Hepatocyte.
Simple model of structural feature of ATP7B protein. Cu=Copper binding motif

Gene edit

Wilson disease protein is associated with ATP7B gene, approximately 80 Kb, located on human chromosome 13 and consists of 21 exons. The mRNA transcribed by ATP7B gene has a size of 7.5 Kb, and which encodes a protein of 1465 amino acids.[5]

The gene is a member of the P-type cation transport ATPase family and encodes a protein with several membrane-spanning domains, an ATPase consensus sequence, a hinge domain, a phosphorylation site, and at least two putative copper-binding sites. This protein functions as a monomer, exporting copper out of the cells, such as the efflux of hepatic copper into the bile. Alternate transcriptional splice variants, encoding different isoforms with distinct cellular localizations, have been characterized.[6] Wilson's disease is caused by various mutations. One of the common mutations is single base pair mutation, H1069Q.[5]

Structure edit

ATP7B protein is a copper-transporting P-type ATPase, synthesized as a membrane protein of 165 KDa in human hepatoma cell line,[5] and which is 57% homologous to Menkes disease-associated protein ATP7A.[7]

ATP7B consists of several domains:

The CPC motif (Cys-Pro-Cys) in transmembrane segment 6 characterizes the protein as a heavy metal transporting ATPase.[8]

The copper binding motif also shows a high affinity to other transition metal ions such as zinc Zn(II), cadmium Cd(II), gold Au(III), and mercury Hg(II). However, copper is able to decrease the zinc binding affinity at low concentration and increase copper binding affinity dramatically with increasing concentration to ensure a strong binding between the motif and copper.[8]

As a P-type ATPases, ATP7B undergoes auto-phosphorylation of a key conserved aspartic acid (D) residue in the DKTGT motif. The ATP binding to the protein initiates the reaction and copper binds to the transmembrane region. Then phosphorylation occurs at the aspartic acid residue in the DKTGT motif with Cu release. Then dephosphorylation of the aspartic acid residue recovers the protein to ready for the next transport.[9]

Function edit

Most of ATP7B protein is located in the trans-Golgi network (TGN) of hepatocytes, which is different from its homologous protein ATP7A.[10] Small amount of ATP7B is located in the brain.[11] As a copper-transporting protein, one major function is delivering copper to copper dependent enzymes in Golgi apparatus (e.g. holo-ceruloplasmin (CPN)).[10]

In the human body, the liver plays an important role in copper regulation including removal of extra copper.[10] ATP7B participates in the physiological pathway in the copper removal process in two ways: secreting copper into plasma and excreting copper into bile.[7]

Interactions edit

ATOX1 edit

ATP7B receives copper from cytosolic protein antioxidant 1 copper chaperone (ATOX1).[5] This protein targets ATP7B directly in liver in order to transport copper. ATOX1 transfers copper from cytosol to the metal binding domain of ATP7B which control the catalytic activity of ATP7B.[12]

Several mutations in ATOX1 can block the copper pathways and cause Wilson disease.[12]

GLRX edit

ATP7B interacts with glutaredoxin-1 (GLRX). Subsequent transport is promoted through the reduction of intramolecular disulfide bonds by GLRX catalysis.[13]

Associations with Wilson's disease edit

Wilson disease happens when accumulation of copper inside the liver causes mitochondrial damage and cell destruction and shows symptoms of hepatic disease. Then, the loss of excretion of copper in bile leads to an increasing concentration of copper level in urine and causes kidney problems. Therefore, symptoms of Wilson's disease could be various including kidney disease and neurological disease.[12] The major cause is the malfunction of ATP7B[12] by single base pair mutations, deletions, frame-shifts, splice errors in ATP7B gene.[5]

See also edit

References edit

  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000123191 - Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000006567 - Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ a b c d e f g h i j Terada K, Schilsky ML, Miura N, Sugiyama T (Oct 1998). "ATP7B (WND) protein". The International Journal of Biochemistry & Cell Biology. 30 (10): 1063–7. doi:10.1016/S1357-2725(98)00073-9. PMID 9785470.
  6. ^ "Entrez Gene: ATP7B ATPase, Cu++ transporting, beta polypeptide".
  7. ^ a b Harris ED (2000). "Cellular copper transport and metabolism". Annual Review of Nutrition. 20: 291–310. doi:10.1146/annurev.nutr.20.1.291. PMID 10940336.
  8. ^ a b Bertini I, Gray H, Stiefel E, Valentine J (2006). Biological inorganic chemistry:structure and reactivity. Sausalito, CA: University Science Books. ISBN 1-891389-43-2.
  9. ^ Banci L, Bertini I, Cantini F, Ciofi-Baffoni S (Aug 2010). "Cellular copper distribution: a mechanistic systems biology approach". Cellular and Molecular Life Sciences. 67 (15): 2563–89. doi:10.1007/s00018-010-0330-x. PMID 20333435. S2CID 41967295.
  10. ^ a b c Lutsenko S, LeShane ES, Shinde U (Jul 2007). "Biochemical basis of regulation of human copper-transporting ATPases". Archives of Biochemistry and Biophysics. 463 (2): 134–48. doi:10.1016/j.abb.2007.04.013. PMC 2025638. PMID 17562324.
  11. ^ Crisponi G, Nurchi VM, Fanni D, Gerosa C, Nemolato S, Faa G (April 2010). "Copper-related diseases: From chemistry to molecular pathology". Coordination Chemistry Reviews. 254 (7–8): 876–889. doi:10.1016/j.ccr.2009.12.018.
  12. ^ a b c d Cox DW, Moore SD (Oct 2002). "Copper transporting P-type ATPases and human disease". Journal of Bioenergetics and Biomembranes. 34 (5): 333–8. doi:10.1023/A:1021293818125. PMID 12539960. S2CID 21471699.
  13. ^ Lim CM, Cater MA, Mercer JF, La Fontaine S (Sep 2006). "Copper-dependent interaction of glutaredoxin with the N termini of the copper-ATPases (ATP7A and ATP7B) defective in Menkes and Wilson diseases" (PDF). Biochem. Biophys. Res. Commun. 348 (2): 428–36. doi:10.1016/j.bbrc.2006.07.067. hdl:10536/DRO/DU:30003772. PMID 16884690. Archived from the original (PDF) on 2021-04-22. Retrieved 2018-10-31.

Further reading edit

External links edit